News on Medial

Related News

PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts

EntrackrEntrackr · 3d ago
PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts
Medial

Snippets PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts Bengaluru-based biopharma company PlasmaGen Biosciences has raised Rs 150 crore led by ViNS Bioproducts along with participation from high-net-worth individuals, family offices, pharma entrepreneurs, and existing investors. The startup is backed by Eight Road Ventures secured the funding at a valuation of over Rs 1,500 crore. PlasmaGen has mopped up over Rs 600 crore in funding to date from Fidelity's FIL Capital Investments, Eight Roads Ventures, F-Prime Capital, and others. The proceeds will be used to scale international operations, expand the product portfolio, and strengthen manufacturing and leadership capabilities, PlasmaGen Biosciences said in a press release. Founded in 2010, PlasmaGen Biosciences focuses on producing and marketing plasma-derived therapies like Immunoglobulin, Albumin, and clotting factors to bridge India's demand-supply gap for these critical medicines, operating a modern fractionation plant in Kolar, Karnataka, and serving neurology, hematology, and critical care, aiming for self-reliance in plasma products. According to PlasmaGen, it has identified distribution partners in key export geographies and is in the process of securing regulatory approvals to begin international sales. India continues to remain a key market for the firm, which is expanding its services across hospitals and physicians through a cold-chain-backed distribution network. PlasmaGen says that it began commercial operations in 2024 at its plasma fractionation facility in Kolar, near Bengaluru. The company asserts that the setup is among only five such facilities in the country and claims that it is the first pure-play plasma biopharma player, has reported strong revenue growth since launch of operations at Kolar and is now preparing to enter overseas markets.

Download the medial app to read full posts, comements and news.